IDEAS home Printed from https://ideas.repec.org/r/ucp/jlawec/y2007v50i1p81-104.html

Does Public Scientific Research Complement Private Investment in Research and Development in the Pharmaceutical Industry?

Citations

Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
as


Cited by:

  1. Sheila Campbell & Jaeger Nelson & Eli Schrag & Heidi Williams & Caleb Wroblewski, 2026. "Estimating the Economic Effects of Federally Funded R&D," NBER Chapters, in: Entrepreneurship and Innovation Policy and the Economy, volume 6, National Bureau of Economic Research, Inc.
  2. Beck, Mathias & Junge, Martin & Kaiser, Ulrich, 2017. "Public Funding and Corporate Innovation," IZA Discussion Papers 11196, IZA Network @ LISER.
  3. Thomas H. W. Ziesemer, 2021. "The Effects of R&D Subsidies and Publicly Performed R&D on Business R&D: A Survey," Hacienda Pública Española / Review of Public Economics, IEF, vol. 236(1), pages 171-205, March.
  4. Gianluca Fabiano & Andrea Marcellusi & Giampiero Favato, 2020. "Public–private contribution to biopharmaceutical discoveries: a bibliometric analysis of biomedical research in UK," Scientometrics, Springer;Akadémiai Kiadó, vol. 124(1), pages 153-168, July.
  5. Raphaël Godefroy, 2010. "The birth of the congressional clinic," Working Papers halshs-00564921, HAL.
  6. Philippe Aghion & Ufuk Akcigit & Antonin Bergeaud & Richard Blundell & David Hemous, 2019. "Innovation and Top Income Inequality," The Review of Economic Studies, Review of Economic Studies Ltd, vol. 86(1), pages 1-45.
  7. Toole, Andrew A., 2012. "The impact of public basic research on industrial innovation: Evidence from the pharmaceutical industry," Research Policy, Elsevier, vol. 41(1), pages 1-12.
  8. Toole, Andrew A. & King, John L., 2011. "Industry-science connections in agriculture: Do public science collaborations and knowledge flows contribute to firm-level agricultural research productivity?," ZEW Discussion Papers 11-064, ZEW - Leibniz Centre for European Economic Research.
  9. Bhaven N. Sampat, 2026. "Taking Stock: The Past and Future of Biomedical Research Funding," NBER Chapters, in: The Economics of Science: Taking Stock and Looking Ahead, National Bureau of Economic Research, Inc.
  10. Shawn Kantor & Alexander Whalley, 2009. "Do Universities Generate Agglomeration Spillovers? Evidence from Endowment Value Shocks," NBER Working Papers 15299, National Bureau of Economic Research, Inc.
  11. Rong, Zhao & Wu, Binzhen, 2020. "Scientific personnel reallocation and firm innovation: Evidence from China’s college expansion," Journal of Comparative Economics, Elsevier, vol. 48(3), pages 709-728.
  12. Toole, Andrew A., 2011. "The impact of public basic research on industrial innovation: Evidence from the pharmaceutical industry," ZEW Discussion Papers 11-063, ZEW - Leibniz Centre for European Economic Research.
  13. Bastian Rake, 2017. "Determinants of pharmaceutical innovation: the role of technological opportunities revisited," Journal of Evolutionary Economics, Springer, vol. 27(4), pages 691-727, September.
  14. Steliana Sandu & Cristina Modoran, 2008. "The Impact Of R&D Investment On Productivity," Annales Universitatis Apulensis Series Oeconomica, Faculty of Sciences, "1 Decembrie 1918" University, Alba Iulia, vol. 2(10), pages 1-18.
  15. Dirk Czarnitzki & Andrew Toole, 2007. "Business R&D and the Interplay of R&D Subsidies and Product Market Uncertainty," Review of Industrial Organization, Springer;The Industrial Organization Society, vol. 31(3), pages 169-181, November.
  16. Deepak Hegde & Bhaven Sampat, 2015. "Can Private Money Buy Public Science? Disease Group Lobbying and Federal Funding for Biomedical Research," Management Science, INFORMS, vol. 61(10), pages 2281-2298, October.
  17. Margaret K. Kyle, 2020. "The Alignment of Innovation Policy and Social Welfare: Evidence from Pharmaceuticals," Innovation Policy and the Economy, University of Chicago Press, vol. 20(1), pages 95-123.
  18. Chen, Sheng-Syan & Chen, Yan-Shing & Liang, Woan-lih & Wang, Yanzhi, 2020. "Public R&D spending and cross-sectional stock returns," Research Policy, Elsevier, vol. 49(1).
  19. Kyle, Margaret K. & Ridley, David B. & Zhang, Su, 2017. "Strategic interaction among governments in the provision of a global public good," Journal of Public Economics, Elsevier, vol. 156(C), pages 185-199.
  20. García-Romero, Antonio & Escribano, Álvaro & Tribó, Josep A., 2017. "The impact of health research on length of stay in Spanish public hospitals," Research Policy, Elsevier, vol. 46(3), pages 591-604.
  21. Kyle, Margaret K., 2022. "Incentives for pharmaceutical innovation: What’s working, what’s lacking," International Journal of Industrial Organization, Elsevier, vol. 84(C).
  22. Office of Health Economics, 2010. "Enhancing the Benefits from Biomedical and Health Research Spillovers," Occasional Paper 000217, Office of Health Economics.
  23. Office of Health Economics, 2010. "Innovation in Medicines: Can We Value Progress?," Seminar Briefing 000219, Office of Health Economics.
  24. Czarnitzki, Dirk & Toole, Andrew A., 2006. "Business R&D and the Interplay of R&D Subsidies and Market Uncertainty," ZEW Discussion Papers 06-055, ZEW - Leibniz Centre for European Economic Research.
  25. Lei Kong, 2020. "Government Spending and Corporate Innovation," Management Science, INFORMS, vol. 66(4), pages 1584-1604, April.
  26. Dubois, Pierre, 2025. "Pharmaceutical Regulation and Incentives for Innovation in an International Perspective," CEPR Discussion Papers 20728, Centre for Economic Policy Research.
  27. Bhaven Sampat, 2022. "Second World War and the direction of medical innovation," WIPO Economic Research Working Papers 70, World Intellectual Property Organization - Economics and Statistics Division.
  28. Rebecca McKibbin & Bruce A. Weinberg, 2021. "Does Research Save Lives? The Local Spillovers of Biomedical Research on Mortality," NBER Working Papers 29420, National Bureau of Economic Research, Inc.
IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.